Form 4: CEL-SCI CEO Geert Kersten Granted 25,000 Stock Options

CEL-SCI Corporation's CEO, Geert R. Kersten, was granted 25,000 stock options with an exercise price of $8.20, vesting over three years.

Summary

• Geert R. Kersten, who serves as Chief Executive Officer, Director, and a 10% owner of CEL-SCI Corp (CVM), was granted 25,000 stock options.
• The options have an exercise price of $8.20 per share.
• The grant date for these options was July 28, 2025, and they are set to expire on July 27, 2035.
• The stock options will vest in three equal annual installments, with the first installment commencing one year after the grant date.
• Following this transaction, Mr. Kersten's beneficial ownership of derivative securities (options) totals 175,157.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally viewed positively as it aligns management's long-term interests with shareholder value, providing an incentive for future performance. It is a routine compensation event.

Positives

• The grant of 25,000 stock options to CEO Geert R. Kersten aligns management incentives with long-term shareholder interests.
• The options have a long expiration date of July 27, 2035, providing a sustained long-term incentive for the CEO.

Negatives

• NA

Risks

• NA

Future Outlook

The vesting schedule of the stock options over three years indicates a long-term incentive structure for the CEO, designed to align future performance with equity ownership and sustained company growth.

Management Comments

• NA

Industry Context

This filing is a standard disclosure of insider equity compensation, a common practice across all industries for publicly traded companies. It reflects a typical mechanism for aligning executive incentives with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a CEO is a common practice in executive compensation across the biotechnology and pharmaceutical industries, similar to companies like Moderna or BioNTech, aiming to incentivize long-term value creation.
• The vesting schedule of three equal annual installments is a standard approach to retain executives and ensure sustained performance, comparable to compensation structures seen at companies such as Amgen or Gilead Sciences.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's interests with long-term stock performance and value creation.

Next Steps

• The first installment of the granted options will vest one year after the grant date of July 28, 2025.
• Subsequent installments will vest annually thereafter for two additional years.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to the CEO as part of their compensation package. While it aligns management incentives with shareholder interests, it does not present new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure for executive compensation.

Keywords

CEL-SCI, CVM, stock options, executive compensation, insider transaction, Geert Kersten, Form 4